MRK

Merck & Co
D

MRK

Arincen67/100B
146.710
USD
-0.21
(-0.14%)
Pre Open·149.010USD+2.300(+1.57%)
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 1.78Revenue estimate 16.29B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

Merck & Co revenue 1985–2026

Merck & Co's revenue in Q3 FY2026, the three months to 30 September 2026, was 18.09B USD, up 5.2% on the same quarter a year before. Merck & Co's revenue over the last twelve months was 67.30B USD, up 4.8% on the twelve months before. In fiscal year 2025 it was 64.93B USD, up 1.2% on the year before.

Last updated 7 Nov 2026 · Next report 2 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202667.30B+4.79%51.79B2.45B
FY202531 Dec 202564.93B+1.18%46.73B18.25B
FY202431 Dec 202464.17B+6.74%48.98B17.12B
FY202331 Dec 202360.12B+1.40%43.99B365.00M
FY202231 Dec 202259.28B+21.72%41.87B14.52B
FY202131 Dec 202148.70B+17.31%35.08B13.05B
FY202031 Dec 202041.52B+6.13%27.90B7.07B
FY201931 Dec 201939.12B-7.50%27.11B9.84B
FY201831 Dec 201842.29B+5.41%28.79B6.22B
FY201731 Dec 201740.12B+0.79%27.21B2.39B
FY201631 Dec 201639.81B+0.78%25.78B3.92B
FY201531 Dec 201539.50B-6.48%24.56B4.44B
FY201431 Dec 201442.24B-4.08%25.47B11.92B
FY201331 Dec 201344.03B-6.84%27.08B4.40B
FY201231 Dec 201247.27B-1.62%30.82B6.17B
FY201131 Dec 201148.05B+4.48%31.18B6.27B
FY201031 Dec 201045.99B+67.66%27.59B861.00M
FY200931 Dec 200927.43B+15.00%18.41B12.90B
FY200831 Dec 200823.85B-1.44%18.27B7.81B
FY200731 Dec 200724.20B+6.90%18.06B3.28B
FY200631 Dec 200622.64B+2.84%16.63B4.43B
FY200531 Dec 200522.01B-4.18%16.86B4.63B
FY200431 Dec 200422.97B+2.17%18.01B5.83B
FY200331 Dec 200322.49B+4.85%18.05B6.83B
FY200231 Dec 200221.45B+1.16%17.54B7.15B
FY200131 Dec 200121.20B-47.48%17.57B7.28B
FY200031 Dec 200040.36B+23.38%19.20B6.82B
FY199931 Dec 199932.71B+21.62%16.32B5.89B
FY199831 Dec 199826.90B+13.80%13.72B5.25B
FY199731 Dec 199723.64B+19.21%12.68B4.61B
FY199631 Dec 199619.83B+18.87%11.24B3.88B
FY199531 Dec 199516.68B+11.43%9.89B3.34B
FY199431 Dec 199414.97B+42.59%9.69B3.00B
FY199331 Dec 199310.50B+8.65%8.39B2.17B
FY199231 Dec 19929.66B+12.32%7.89B1.98B
FY199131 Dec 19918.60B+12.14%6.93B2.12B
FY199031 Dec 19907.67B+17.11%6.15B1.78B
FY198931 Dec 19896.55B+10.29%5.22B1.50B
FY198831 Dec 19885.94B+17.35%4.62B1.21B
FY198731 Dec 19875.06B+22.58%3.83B906.40M
FY198631 Dec 19864.13B+16.39%2.98B675.70M
FY198531 Dec 19853.55B—2.46B539.90M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Merck & Co revenue growth by segment

Q3 FY2026 against Q3 FY2025

Animal Health1.68B
+3.8%
Pharmaceutical141.00M
-99.1%

Merck & Co revenue by segment over time

Pharmaceutical Animal Health Other Segments
Fiscal yearPharmaceuticalAnimal HealthOther Segments
FY202558.14B +1.3%6.35B +8.1%515.00M -42.2%
FY202457.40B +7.1%5.88B +4.5%891.00M -1.8%
FY202353.58B +3.0%5.63B +1.4%907.00M -47.5%
FY202252.01B +21.6%5.55B -0.3%1.73B +352.4%
FY202142.75B -0.6%5.57B +18.4%382.00M +1,560.9%
FY202043.02B +3.0%4.70B +7.1%23.00M -96.7%
FY201941.75B +10.8%4.39B +4.3%696.00M +77.1%
FY201837.69B +6.5%4.21B 393.00M -91.7%
FY201735.39B +0.7%— 4.73B +1.6%
FY201635.15B +1.1%— 4.66B -1.3%

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Merck & Co's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.